← Leaderboards
Dejian Lai
University Of Texas Hlth Sci Ctr Houston
$1,435,351
Attributed
$1,435,351
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $360.6K · FY2021–24$500K$375K$250K$125K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$1,435,351 · 1
By mechanism
U24$1,435,351 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Joy Marie Schmitz$16,485,851
- Radha Korupolu$354,752
- Chelsea Gilts Ratcliff$354,752
- Eva M Sevick-Muraca$18,367,261
- Jin Ho Yoon$659,208
Others in their field
Other Emerging Leaders on “Common Data Element”
- Dwayne Forquer · Leidos Biomedical Research, Inc.$50,844,487
- Kathleen Maletic Neuzil · Emory University$27,466,472
- Jean Macdonald · Dana-Farber Cancer Inst$26,990,229
- Emmanuel Aja Oga · Research Triangle Institute$16,888,225
- Rene S. Kahn · Icahn School Of Medicine At Mount Sinai$13,629,024
- Maurizio Macaluso · Cincinnati Childrens Hosp Med Ctr$12,545,935
Research focus
Common Data ElementCollaborationsCollectionAdherenceAnastomosis - ActionAdverse EventAdverse Event MonitoringAuthorityAllogenicAdherence RateBig Data MethodsBiometryBudgetsAncillary StudyAnnual ReportsCase Report FormCertificationChildClinical CenterClinically RelevantClinical ManagementClinical TrialsClinical Trials Data Monitoring CommitteesCommunication
Grant awards (4)
The Allogeneic Human Mesenchymal Stem Cell (MSCs) injection in Patients with Hypoplastic Left Heart Sydrome: A Phase IIb Clinical Trial (ELPIS)$353,428
U24 · FY2024 · HL · contact PI
The Allogeneic Human Mesenchymal Stem Cell (MSCs) injection in Patients with Hypoplastic Left Heart Sydrome: A Phase IIb Clinical Trial (ELPIS)$360,641
U24 · FY2023 · HL · contact PI
The Allogeneic Human Mesenchymal Stem Cell (MSCs) injection in Patients with Hypoplastic Left Heart Sydrome: A Phase IIb Clinical Trial (ELPIS)$360,641
U24 · FY2022 · HL · contact PI
The Allogeneic Human Mesenchymal Stem Cell (MSCs) injection in Patients with Hypoplastic Left Heart Sydrome: A Phase IIb Clinical Trial (ELPIS)$360,641
U24 · FY2021 · HL · contact PI